Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 4/20 | 0.48 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 10/20 | 0.42 |
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14070058 | 1.00 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL5856801 | 1.00 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL14499820 | 0.80 | TSHR (0.46) | TSHRBRD4 | |
| SCHEMBL5638542 | 0.80 | TSHR (0.46) | TSHRBRD4 | |
| SCHEMBL5638546 | 0.80 | TSHR (0.46) | TSHRBRD4 | |
| SCHEMBL18797562 | 0.79 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL21413387 | 0.79 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL21987681 | 0.79 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL18797542 | 0.79 | GABRR1 (0.48) | GABRR1GABRR2CA1CA2CA9 | |
| SCHEMBL14499819 | 0.77 | SLC6A12 (0.46) | TSHRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008112251-A1 | CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES | PROGEN PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | GABRR1 109/4885GABRR2 158/4885CA1 2031/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | GABRR1 54/4885GABRR2 75/4885CA1 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.